Viewing Study NCT02766335


Ignite Creation Date: 2025-12-24 @ 10:30 PM
Ignite Modification Date: 2026-02-28 @ 9:43 PM
Study NCT ID: NCT02766335
Status: COMPLETED
Last Update Posted: 2023-05-25
First Post: 2016-05-06
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Sponsor: SWOG Cancer Research Network
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Recurrent Squamous Cell Lung Carcinoma View
None Stage IV Squamous Cell Lung Carcinoma AJCC v7 View
Keywords: